Introduction
============

The normal pumping action of the mammalian heart is critically dependent on the cardiac electrophysiological function. Within a heartbeat, the single cardiac cell generates an action potential in consequence of sequential depolarizing and repolarizing currents. The exact function of the multitude of ion channels and other transporters of electrical charges determines the morphology of the action potential. Owing to diversities in properties and expression profiles of ion channels in different regions in the heart, in different species and in different physiological and pathological settings, the action potential waveform is highly variable (Carmeliet, [@B15]; Nerbonne and Kass, [@B53]; Nattel et al., [@B52]; Ter Keurs and Boyden, [@B78]).

The human action potential has a spike-and-dome morphology, with a rapid early repolarizing phase or notch that reflects the transient outward potassium current, *I*~to~. The magnitude of the notch determines the membrane potential for the plateau phase of the action potential, and thus establishes the driving force for Ca^2+^ entry through the L-type Ca^2+^ channel triggering calcium-induced calcium release and contraction of the myocyte (Greenstein et al., [@B29]; Sah et al., [@B73]). In rodents, *I*~to~ is the major repolarizing force abbreviating the action potential considerably in adaptation to the fast heart rates. Reduced *I*~to~ amplitude in non-rodent mammals is associated with desynchronized Ca^2+^ release from intracellular stores (Harris et al., [@B34]; Wasserstrom et al., [@B84]) and suboptimal cardiac performance secondary to uncoordinated calcium-induced calcium release and contraction (Sah et al., [@B72], [@B73]; Cordeiro et al., [@B16]).

The landmark finding of reduced *I*~to~ in heart failure (Beuckelmann et al., [@B7]) spurred an intense interest into function and regulation of this current. An et al. ([@B3]) reported how *I*~to~ was modulated by K^+^-channel interacting proteins (KChIPs). Since the initial characterization of KChIPs, several additional functions of KChIPs have been described, including tuning of several ionic currents and gene-transcription regulation (Buxbaum, [@B11]). In the present review, we outline the basic molecular biology and cardiac electrophysiology of KChIP2 and integrate these findings in a discussion of the role of KChIP2 in cardiac plasticity, hypertrophic remodeling, arrhythmia, and failure.

KChIP Structure and Expression
==============================

The KChIPs belong to the family of small cytosolic calcium-binding proteins and consists of four different KChIP isoforms ranging between 216 and 270 amino acids. They all have a reasonably conserved core region of 185 amino acids and a heterogeneous N-terminal part (An et al., [@B3]; Holmqvist et al., [@B36]). All KChIPs have calcium-binding EF hands which appear important for modulation K~V~-channels (An et al., [@B3]; Li et al., [@B43]) but not for Ca~V~-channels (Thomsen et al., [@B82]). Myristoylation of KChIP1 (Burgoyne and Weiss, [@B10]) and palmitoylation of KChIP2 (Takimoto et al., [@B77]) play important roles in post-translational modification to improve plasma membrane localization. It is well established that KChIP1--3 functionally increase peak K~V~4 current, slow channel inactivation and accelerate recovery from inactivation (An et al., [@B3]; Lundby et al., [@B47]); whereas KChIP4 eliminates inactivation (Holmqvist et al., [@B36]). Furthermore, KChIP2 has been reported to increase *I*~Ca,L~ (Thomsen et al., [@B82]), and suggested to decrease K~V~1.5 cell surface expression (Li et al., [@B43]) and facilitate *I*~Na~ (Deschenes et al., [@B18]).

All four KChIP mRNAs are found in the brain; however only KChIP2 is expressed in the heart (An et al., [@B3]; Kuo et al., [@B41]; Rosati et al., [@B67]). KChIP expression in cardiac autonomic nerves has not been reported. The cardiac KChIP2 gene generates three protein isoforms of 220, 252, and 270 amino acids via alternative splicing of exons 2 and 3 (Kuo et al., [@B41]). Immunocytochemistry has localized KChIP2 to the sarcolemma and the nucleus (Deschenes et al., [@B19]). Cardiac expression of KChIP2 is absent in embryonic and neonatal stages; however developmental upregulation potentially suggests a physiological role for KChIP2 once a transmural gradient of *I*~to~ is appearing (Kuo et al., [@B41]; Plotnikov et al., [@B62]). KChIP2 is expressed heterogeneously across the canine and human left and right ventricular free wall with higher concentrations in epicardium compared to endocardium, whereas no transmural gradient of expression is found for K~V~4.3 (Rosati et al., [@B67], [@B66]; Calloe et al., [@B13]). This finding has led to the suggestion that KChIP2 is responsible for the *I*~to~ gradient; whereas other studies failed to show a transmural KChIP2 protein gradient in canine and human hearts (Deschenes et al., [@B19]), arguing against the role of KChIP2 in the generation of the transmural *I*~to~ gradient. More recently, studies of the human heart have shown strong KChIP2 expression in the epicardium based on both mRNA and protein levels (Gaborit et al., [@B26]; Soltysinska et al., [@B75]). In mice, transmural K~V~4.2 protein expression parallels the *I*~to,f~ gradient; whereas K~V~4.3 and KChIP2 protein levels were uniformly distributed in an early study (Guo et al., [@B33]). More recently, laser capture microdissection of the murine LV has revealed a transmural gradient of both K~V~4.2 and KChIP2 mRNA (Teutsch et al., [@B79]).

KChIP2 and Ion Channels
=======================

K~V~4
-----

KChIP2 is a cytosolic protein when expressed in absence of K~V~4; however co-expression of K~V~4 and KChIP2 leads to co-localization at the cell surface (An et al., [@B3]; Bahring et al., [@B5]). Biochemically, KChIP2 co-immunoprecipitates with K~V~4.2 and K~V~4.3 in mouse ventricular homogenates (Guo et al., [@B33]). Crystallographic, electron microscopic and electrophysiological experiments have shown that KChIPs physically interact with the distal part of N-terminus of K~V~4 subunits, forming a cross-shaped octamer, where two interaction sites on each K~V~4 subunit are important for KChIP2-mediated channel trafficking and gating (Bahring et al., [@B5]; Kim et al., [@B40]; Pioletti et al., [@B61]). KChIP2 decreases the turnover rate of K~V~4.2 by stabilizing the KChIP2--K~V~4.2 complex at the cell surface. This stabilization is lost with deletion of the N-terminal part of K~V~4.2 (Foeger et al., [@B25]). KChIP2 protein levels are decreased in the absence of K~V~4.2, despite unaltered mRNA levels, suggesting post-translational downregulation of KChIP2 in the absence of the pore-forming subunit (Guo et al., [@B31]). In addition, both K~V~4.2 and K~V~4.3 mRNA and protein expression are augmented in hearts from KChIP2^−/−^ mice as well as in cultured neonatal rat cardiomyocytes overexpressing KChIP2, suggesting regulation of the pore-forming subunits at gene and protein levels (Thomsen et al., [@B81]; Jin et al., [@B37]).

The rodent outward potassium currents (Figure [1](#F1){ref-type="fig"}) involved in action potential repolarization can broadly be divided into transient outward (*I*~to~) and delayed rectifier (*I*~K~) currents (for a review, see Nerbonne et al., [@B54]), which can be further separated into four components, *I*~to,fast~ (*I*~to,f~, K~V~4.2/K~V~4.3 + KChIP2), *I*~to,slow~ (*I*~to,s~, K~V~1.4), *I*~K,slow1~ (*I*~Kur~, K~V~1.5), and *I*~k,slow2~ (*I*~SS~, K~V~2.1). In order to dissect these current components, several studies have used electrophysiology combined with pharmacology on cardiomyocytes of wild-type (WT) or transgenic mice (Himmel et al., [@B35]; Brouillette et al., [@B8]; Brunet et al., [@B9]; Liu et al., [@B44]). *I*~to,f~ and *I*~to,s~ both have a fast activation and a fast inactivation and are under normal conditions very similar, however they can be distinguished by the rate of recovery from inactivation (Wickenden et al., [@B86]; Patel and Campbell, [@B59]). *I*~to,f~ recovers from inactivation in the order of milliseconds, whereas *I*~to,s~ recovers much slower. In order to inhibit *I*~to,f~, an inactivating pre-pulse to −40 mV for 50 ms can be applied, which captures *I*~to,f~ in a closed state (Brouillette et al., [@B8]); alternatively *Heteropoda* toxin can be used, which selectively blocks K~V~4 channels in low-micromolar concentrations (Sanguinetti et al., [@B74]; DeSimone et al., [@B20]; Liu et al., [@B44]). For evaluating *I*~K,slow1~, the sensitivity toward 4-aminopyridine can be exploited, because *I*~K,slow1~ is sensitive in the micromolar range while *I*~to,f~, *I*~to,s~, and *I*~K,slow2~ are sensitive in the millimolar range (Guo et al., [@B32]). Furthermore, in order to dissect *I*~K,slow2~, an inactivating pre-pulse in combination with micromolar 4-aminopyridine can be used (Brouillette et al., [@B8]). Several studies have failed to find *I*~to,s~ in the free wall of the mouse ventricle and only located it in myocytes from the interventricular septum (London et al., [@B46]; Guo et al., [@B32]).

![**Whole-cell voltage-clamp recordings of outward K-currents recorded in disaggregated left ventricular cardiomyocytes from wild-type (WT) versus KChIP2^−/−^ mice**. Cardiomyocyte isolation and patch-clamp solutions (37°C) were made according to (Brouillette et al., [@B8]) with minor modifications. Cadmium (300 μM) was added to inhibit L-type Ca^2+^ currents. **(A)** Representative current traces showing that KChIP2^−/−^ cardiomyocytes lack a fast decaying component of the outward K-current (solid arrows). **(B)** Peak current density as a function of test potential, however, was not significantly changed at any voltage (inset, voltage protocol). **(C)** The decay of the outward current (0--700 ms) was fitted to a second-order exponential function to obtain time-constants (τ) of inactivation for positive test potentials. No differences between WT and KChIP2^−/−^ were found for the slow component; however, the fast component of the current decay was significantly slower for KChIP2^−/−^ myocytes, confirming the loss of a transient component. **(D)** In order to dissect *I*~K,slow1~ from *I*~to,f~, the current sensitive to 100 μM 4-AP was determined. The 4-AP sensitive fraction (red) of the peak current (blue, normalized to 1) was increased in KChIP2^−/−^ compared to WT, indicating increased *I*~K,slow1~. **(E)** Recovery from inactivation was addressed by a double-pulse voltage-clamp protocol with varying interpulse intervals (see inset). Representative current traces from WT and KChIP2^−/−^ cardiomyocytes are presented. **(F)** The mean recovery from inactivation is illustrated as the peak current during the 0.2-s test pulse relative to the 1.5-s base pulse. Recovery from inactivation was significantly slowed in KChIP2^−/−^ compared to WT in interpulse intervals between 1 and 4000 ms. This is compatible with a larger fraction on the outward potassium currents attributable to *I*~K,slow~ relative to *I*~to,f~ in KChIP2^−/−^ cardiomyocytes. Data are reported as mean ± SEM. Statistical significance was evaluated by ANOVA followed by Newman--Keuls' *post hoc* test where appropriate. \**p* \< 0.05. Comparable data have been published previously by Thomsen et al. ([@B81]).](fphys-03-00118-g001){#F1}

Electrophysiologically, KChIP2 increases K~V~4-mediated current amplitude and modulates channel gating by slowing the fast time constant of inactivation at depolarizing potentials and accelerating recovery from inactivation (Decher et al., [@B17]; Deschenes et al., [@B19]; Patel et al., [@B60]). The binding of KChIP2 to K~V~4 is calcium-independent; however the effect of KChIP2 on slowing the fast time constant of inactivation at depolarizing potentials is dependent on calcium-binding to three of the four EF hands on KChIP2 (Deschenes et al., [@B19]; Patel et al., [@B60]). Interestingly, when K~V~4 and KChIP2 are co-expressed in HEK293 the current inactivation is much slower than the native *I*~to~ in human and canine cardiomyocytes (Deschenes et al., [@B19]), which could be explained by the presence of additional subunits in the native cardiac cell. Dipeptidyl-peptidase-like proteins (DPPX) have been suggested as part of the missing link since a ternary complex of K~V~4.3, KChIP2, and DPPX produced currents closely resembling *I*~to,f~ in mammalian expression systems (Radicke et al., [@B65]; Lundby et al., [@B47]). Additionally, KCNE2--4 have all been implicated in regulation of the K~V~4-mediated current, suggesting a diverse macromolecular complex governing *I*~to~ (Zhang et al., [@B89]; Lundby and Olesen, [@B48]; Lundby et al., [@B47]).

The development of the KChIP2 deficient mouse provided the first clues to the role of KChIP2 in generating the native *I*~to~ (Kuo et al., [@B41]). Voltage-clamp recordings of KChIP2^−/−^ cardiomyocytes revealed a complete loss of *I*~to,f~ defined as the portion of the potassium currents sensitive to an inactivating voltage pre-pulse to −40 mV. Moreover, administration of *Heteropoda* toxin to KChIP2^−/−^ cardiomyocytes had no effect on potassium current amplitude (Thomsen et al., [@B81]). *In vivo*, the loss of *I*~to,f~ translated to an elevated and earlier J wave of the murine ECG, normal QT intervals and ventricular effective refractory periods, and susceptibility to pacing-induced polymorphic ventricular tachyarrhythmias (Kuo et al., [@B41]). Furthermore, we showed that transmembrane action potentials were comparable in ventricular multicellular preparations from KChIP2^−/−^ and WT control mice paced at 2 Hz (Thomsen et al., [@B82]), which was presumably secondary to an upregulation of a 4-aminopyridine-sensitive current that restored peak outward potassium current density in KChIP2^−/−^ mice (Figure [1](#F1){ref-type="fig"}). Action potentials recorded from disaggregated right ventricular myocytes from KChIP2^−/−^ mice are longer than those from WT mice and show reverse rate dependency (Kuo et al., [@B41]), potentially consequential of the slowed recovery from inactivation of the remaining outward potassium currents (Figure [1](#F1){ref-type="fig"}).

Ca~V~1.2
--------

KChIP2 binds to the N-terminal cytosolic domain of Ca~V~1.2 in a calcium-independent manner. In heterologous expression systems, KChIP2 co-expression causes an increase in current mediated by Ca~V~1.2, comparable to the effect of the calcium channel auxiliary β~2~ subunit; however KChIP2 was not able to replace the β~2~-mediated macromolecular ion channel trafficking to the cell membrane (Thomsen et al., [@B82]). Also this functional modulation was independent of calcium-binding to the EF hands of KChIP2. Furthermore, the L-type calcium current is significantly smaller in disaggregated cardiomyocytes from KChIP2^−/−^ mice compared to WT controls (Figure [2](#F2){ref-type="fig"}). This decrease in current density was observed in the presence of an intact trafficking pathway of Ca~V~1.2 and increased transcriptional activity of the β~2~ subunit (Thomsen et al., [@B80],[@B82]). Protein levels of Ca~V~1.2 in the KChIP2^−/−^ mice are increased, whereas acute gene silencing of KChIP2 in neonatal rat cardiomyocytes does not affect Ca~V~1.2 protein expression (Deschenes et al., [@B18]). In addition, in neurons KChIP3 has been described as part of a macromolecular signaling complex together with Ca~V~3 and K~V~4 that confer physiological calcium modulation of K~V~4-mediated currents (Anderson et al., [@B4]).

![**L-type Ca^2+^ current in disaggregated cardiomyocytes from wild-type (WT) versus KChIP2^−/−^**. *I*~Ca,L~ was recorded at 37°C in left ventricular cardiomyocytes as the current fraction sensitive to 300 μM Cd^2+^, as described by Sah et al. ([@B72]) with minor modifications. **(A)** Representative current traces of WT and KChIP2^−/−^ (inset, voltage protocol). **(B)** Mean peak current densities show a decreased *I*~Ca,L~ in KChIP2^−/−^ cardiomyocytes. **(C)** No changes were found in the steady-state inactivation of *I*~Ca,L~ in WT versus KChIP2^−/−^ cardiomyocytes (inset, voltage protocol). Data are reported as mean ± SEM. Statistical significance was evaluated by ANOVA followed by Newman--Keuls' *post hoc* test where appropriate. \**p* \< 0.05. Comparable data have been published previously by Thomsen et al. ([@B82]).](fphys-03-00118-g002){#F2}

Na~V~1.5
--------

A structural and functional association of *I*~to~ and *I*~Na~ has been suggested based on data from neonatal rat cardiomyocytes (Deschenes et al., [@B18]). Genetic silencing of KChIP2 caused a decrease in protein contents of K~V~4.2 and K~V~4.3, presumably due to a trafficking defect. Interestingly, the authors showed a biochemical association between K~V~4 and the auxiliary β~1~ subunit of the sodium channel, and went on to demonstrate that KChIP2 silencing also dramatically reduced mRNA and protein levels of Na~V~1.5 and the sodium channel β~1~ subunit to a point where no *I*~Na~ could be recorded and no action potentials could be elicited (Deschenes et al., [@B18]). Reversibly, co-expression of KChIP2 with Na~V~1.5 in a mammalian cell line augmented the sodium current, further substantiating the functional effect of KChIP2 on *I*~Na~ (Deschenes et al., [@B18]), suggesting a close structural and functional link of *I*~to~ and *I*~Na~. These findings are not reproduced in mice with complete deletion of KChIP2 as they do not show embryonic lethality which would be expected if *I*~Na~ was reduced to the point the hearts were inexcitable (Kuo et al., [@B41]). The KChIP2^−/−^ mice show a small, but statistically not significant, reduction of the upstroke velocity of action potentials, generally accepted to be an indication of *I*~Na~ availability (Thomsen et al., [@B81]). Furthermore, mRNA levels for Na~V~1.5 and β~1~ are comparable in KChIP2^−/−^ mice and WT controls (M Thomsen, unpublished data). The reason underlying the discrepant results is currently unknown, but could include an unidentified compensatory adaptation in the embryogenic development of the knockout mouse to counteract a reduction in *I*~Na~.

K~V~1.5
-------

K~V~1.5 governs the murine *I*~K,slow~ and the human atrial-specific *I*~Kur~. In HEK-293 cells, KChIP2 has been reported to reduce K~V~1.5 current density without modifying the kinetics of the current (Li et al., [@B43]). Immunocytochemistry suggested that KChIP2 attenuate trafficking of K~V~1.5 to the plasma membrane and EF-hand mutations abolished the effect of KChIP2. In the same study, mouse ventricular K~V~1.5 and KChIP2 were found to co-immunoprecipitate (Li et al., [@B43]). However, co-expression of K~V~1.5 with KChIP2 in *Xenopus laevis* oocytes revealed no difference in current levels in absence or presence of KChIP2 (Lundby et al., [@B47]). Additionally, both groups found no effect of KChIP2 on Kv1.4 currents (Li et al., [@B43]; Lundby et al., [@B47]). In KChIP2^−/−^ mice, K~V~1.5 mRNA levels were elevated in KChIP2^−/−^ hearts, suggesting a potential KChIP2-mediated regulation of Kv1.5 on a transcriptional level.

KChIP2 and Arrhythmias
======================

Spontaneous ventricular arrhythmias are rarely seen in mice with genetic deletion of single potassium currents (Nerbonne et al., [@B54]). For example, the K~V~4.2^−/−^ mouse show complete elimination of *I*~to,f~ but normal action potentials and ECG and no spontaneous arrhythmia (Guo et al., [@B31]). On the other hand, prolonged action potentials and QT intervals were reported in another mouse model with total elimination of *I*~to,f~ (K~V~4.2-W362F; Barry et al., [@B6]). Interestingly, overexpression of a dominant-negative K~V~4.2 fragment generated a mouse line with reduced *I*~to,f~, prolonged action potentials and hypercontractility that developed into heart failure within 3 months of age (Wickenden et al., [@B87]).

The KChIP2^−/−^ mouse had no spontaneous arrhythmia during continuous monitoring of conscious mice; however, it was possible to induce cardiac tachyarrhythmia by pacing the ventricles (Kuo et al., [@B41]). Presently, it is unclear whether the increased susceptibility to pacing-induced arrhythmias is secondary to decreased repolarizing potassium currents or decreased depolarizing calcium currents, or a combination of the two.

KChIP2 and Remodeling
=====================

Cardiac memory
--------------

Cardiac memory describe a special form of cardiac plasticity observed as an altered T wave on the surface ECG (Rosenbaum et al., [@B70]). After a period of altered ventricular activation, due to pacing or arrhythmias, the T wave "remembers" the QRS complex from the paced or arrhythmic phase. The electrocardiographic T wave vector during sinus rhythm reflects the QRS complex vector during the preceding period of ventricular activation (Rosen, [@B68]).

Cardiac memory in dogs is associated with a decrease in *I*~to~ and a reduction in K~V~4.3 mRNA and KChIP2 mRNA and protein (Yu et al., [@B88]; Patberg et al., [@B58]). K~V~4.2, KChIP2, and the angiotensin-1 receptor co-localize and immunoprecipitate together in heart tissue (Doronin et al., [@B24]). Furthermore, when ventricular pacing alters cardiac stretch, angiotensin-II is released (Sadoshima and Izumo, [@B71]). Activation of the angiotensin-1 receptor results in an internalization of the macromolecular complex and a decrease in *I*~to~ density. Secondly, during prolonged periods of ventricular pacing inducing cardiac memory, cyclic AMP response element binding protein (CREB) is downregulated via ubiquitination and proteosomal degradation (Ozgen et al., [@B55]). Transcriptional activity of KChIP2 is reduced by low levels of CREB as this fails to associate with cyclic AMP response elements in the KChIP2-gene promotor region, indirectly causing a further reduction in *I*~to~ (Patberg et al., [@B57]). In summary, altered ventricular pacing causes a rapid internalization if the K~V~4 ion channel complex and a reduction in KChIP2 levels further reducing *I*~to~ (Rosen and Cohen, [@B69]). Angiotensin-1 receptor blockade do not suppress the latter pathway, whereas inhibition of *I*~Ca,L~ attenuates cardiac memory and *I*~to~ downregulation, suggesting a role central for calcium handling in the development of cardiac memory (Plotnikov et al., [@B63]).

Hypertrophy
-----------

Hypertrophic enlargement of the ventricles involves complex cellular processes, and is typically divided into concentric hypertrophy due to pressure overload and eccentric hypertrophy due to volume overload. Hypertrophy is associated with growth of the individual cardiomyocyte which adds sarcomeres to the existing contractile apparatus, thus responding to the increased demand on the ventricle. In contrast, the failing heart cannot compensate sufficiently, and is impaired in its ability to sustain an adequate blood flow to the body. Among a plethora of changes, cardiac hypertrophy is accompanied by electrophysiological remodeling causing prolonged action potential durations (Gaughan et al., [@B27]; Kaab et al., [@B38]; Marionneau et al., [@B49]). Ion channel remodeling in cardiac hypertrophy and failure has been described recently in excellent reviews (Nattel et al., [@B52]; Nass et al., [@B51]; Aiba and Tomaselli, [@B1]). Here, we focus on KChIP2.

Modulating *I*~to~ affects action potential duration, intracellular calcium load and contractile force in a complex manner. In larger mammals, pharmacological activation of *I*~to~ lead to prolongation of the action potential in a concentration-dependent manner (Calloe et al., [@B12]). Moreover, large increases in *I*~to~ to a point where Ca~V~1.2 fails to activate, action potentials show a dramatic shortening (Greenstein et al., [@B29]; Sah et al., [@B73]; Calloe et al., [@B14]). Selective pharmacological inhibition of *I*~to,f~ in species with a spike-and-dome morphology action potential is yet to be studied.

In rodents, *I*~to~ is part of the terminal repolarization and action potential prolongation is consistently seen in the absence of the current (Nerbonne et al., [@B54]). This action potential prolongation elevates cytosolic calcium levels and improves excitation--contraction coupling by mechanisms distinct from the effects of *I*~to~ modulation in larger mammals (Sah et al., [@B73]). Furthermore, an elevated calcium level activates the calcium-sensitive phosphatase calcineurin and initiates hypertrophic signaling (Kassiri et al., [@B39]; Zobel et al., [@B91]; Lebeche et al., [@B42]). Transcriptional regulation of many hypertrophic genes is regulated via NFAT by the activity of calcineurin (Gaughan et al., [@B27]; Zobel et al., [@B91]; Gong et al., [@B28]; Jin et al., [@B37]). It appears that an increased cytosolic calcium concentration during adrenergically induced hypercontractility activates calcineurin initiating the hypertrophic response. Hypertrophy is not observed in models with genetically reduced *I*~to,f~ in the absence of action potential prolongation, potentially due to chronic upregulation of other repolarizing currents (Kuo et al., [@B41]; Guo et al., [@B31]). Interestingly, concentric hypertrophy in WT mice secondary to aortic banding is associated with prolonged action potentials, decreased *I*~to,f~ and an increased protein level of the ion channel underlying *I*~K,slow1~ (Marionneau et al., [@B49]), whereas angiotensin-II mediated hypertension causing cardiac hypertrophy leaves *I*~to,f~ density and K~V~4.2, K~V~4.3, and KChIP2 protein contents unaltered.

Using KChIP2 overexpression to successfully prevent hypertrophy in rats showed that a KChIP2-mediated upregulation of *I*~to~ shortened action potentials and reduced myocardial shortening (Jin et al., [@B37]). In the same study, the authors showed that KChIP2 overexpression decreased calcineurin expression *in vitro*, suggesting that action potential shortening abrogates the hypertrophic response via the calcineurin pathway. Moreover, simultaneous overexpression of K~V~4.3 and induction of concentric hypertrophy in rat hearts showed a robust increase in *I*~to~, action potential abbreviation, reduced calcineurin expression and an attenuated hypertrophic response (Lebeche et al., [@B42]).

Transgenic mice overexpressing calcineurin have a reduced *I*~to,f~, prolonged action potential duration and display cardiac hypertrophy, which could all be reversed by pharmacological inhibition of calcineurin (Dong et al., [@B22], [@B23]). In young mice overexpressing calcineurin, a paradoxical increased *I*~to,f~ was measured, secondary to elevated K~V~4.2 expression (Gong et al., [@B28]). It was hypothesized that two regulatory pathways operated in parallel, one leading to positive regulation of K~V~4.2 transcription via activation of calcineurin and NFAT translocation (Gong et al., [@B28]); and one that via NF-κB phosphorylation reduces *I*~to,f~ via downregulation of KChIP2 and K~V~4.3 (Panama et al., [@B56]).

Heart failure
-------------

Heart failure is the condition, where the ability of the heart to adequately supply blood flow to meet the demand of the body is impaired. Whereas the underlying index events are often manageable if identified early, treatment options for heart failure are mainly palliative or merely slowing the relentless progression of symptoms (Dickstein et al., [@B21]). At end-stage heart failure, therapeutic options are heart transplantation or mechanical support devices. The lifetime risk of acquiring heart failure is estimated to 20% (Lloyd-Jones et al., [@B45]) and the 5-year mortality rate after diagnosis is 50% (Stewart et al., [@B76]).

Functional reduction of *I*~to~ has been observed in many animal models of heart failure (Nass et al., [@B51]) in addition to human samples from terminal heart failure transplants (Beuckelmann et al., [@B7]; Wettwer et al., [@B85]; Nabauer et al., [@B50]). K~V~4.3 mRNA is reduced in human (Kaab et al., [@B38]) and canine heart failure (Akar et al., [@B2]). KChIP2 mRNA and protein is downregulated in human heart failure (Radicke et al., [@B64]; Soltysinska et al., [@B75]), although reports of unchanged KChIP2 levels are also available (Zicha et al., [@B90]). Heart failure secondary to pressure overload reduces peak potassium currents in mice, but does not completely abolish *I*~to,f~ (Wang et al., [@B83]; Grubb et al., [@B30]). Furthermore, preliminary studies show a reduction of non-*I*~to,f~ currents in KChIP2^−/−^ mice with heart failure, adding another layer of complexity to the electrophysiological remodeling seen in heart failure (Grubb et al., [@B30]).

Limitations
===========

In order to translate findings in experimental models to useful information in a clinical setting, a clear understanding of species dependent differences is electrophysiology of rodents and larger mammals is imperative. Compatible with having a higher heart rate than larger mammals, rodents have a much shorter action potential and *I*~to~ is involved with total repolarization, whereas it constitutes the notch between the spike-and-dome in the action potential of larger mammals (for review, see Nerbonne et al., [@B54]). In rodents, a loss of *I*~to~ leads to a prolonged APD which results in a loss of temporal synchronization of the Ca^2+^ entry through *I*~Ca,L~ due to channel inactivation instead of deactivation causing a longer Ca^2+^ entry and a stronger but less synchronized SR Ca^2+^ release. In larger mammals, instead of being responsible for *I*~Ca,L~ deactivation, *I*~to~ provides a driving force for Ca^2+^ entry, and a decreased *I*~to~ therefore leads to an *I*~Ca,L~ reduction and a desynchronized intracellular Ca^2+^-transient (for review, see Sah et al., [@B73]). This is an important species dependent difference, and should be considered when using rodents as a model of hypertrophy or heart failure. Moreover, extrapolation of physiological data from rodent studies to clinical practice should always be performed with outmost caution and only with supporting results from additional experimental models and human trials.

The KChIP2^−/−^ mouse does not show any apparent pathology; however, it is not uncommon that knockout animals lack phenotypic changes which may be due to a redundancy of genes that can compensate for the reduced repolarization reserve. The KChIP2^−/−^ mouse is not an organ-specific knockout, which may have unspecific, peripheral effects compared to a cardiac-specific knockout mice, since many genes are expressed in several organs, including KChIP2 (An et al., [@B3]). Furthermore, the knockout of KChIP2 is congenital and non-inducible, which means that remodeling in the knockout animal could happen during development. This could be avoided by using an inducible organ-specific knockout or a tissue specific gene transfer by viral infection, which would also be preferable for studying the remodeling in hypertrophy or heart failure, since no pre-existing remodeling would exist.

Summary and Concluding Remarks
==============================

Substantial progress has been made in the mapping of the multiple characteristics and roles of KChIP2 in the heart. KChIP2 have been reported to modulate K~V~1.5, K~V~4.2, K~V~4.3, Ca~V~1.2, and Na~V~1.5. Both K~V~4.2 and K~V~4.3 are intimately regulated by KChIP2, where peak current is increased, inactivation kinetics are slowed and recovery from inactivation is accelerated by the presence of KChIP2 (An et al., [@B3]). Ca~V~1.2-conducted current is increased by KChIP2 via a potential interaction at the amino-terminal inhibitory module on the α~1C~ subunit of the L-type Ca^2+^ channel (Thomsen et al., [@B82]). Conflicting reports regarding KChIP2-mediated modulation of K~V~1.5 and Na~V~1.5 exists and points toward areas where intensified research is required to resolve discrepancies and clarify our understanding of cardiac electrophysiology. Cardiac memory, hypertrophy, and failure are all associated with reductions in KChIP2 and it appears that overexpression of KChIP2 can prevent the development of hypertrophy in rats (Jin et al., [@B37]).

Several aspects remains poorly understood, however. Given the promiscuity of KChIP2, it is possible that additional binding partners will be identified, potentially in non-cardiac tissue. The physiological relevance of the many individual interactions needs to be tested and compared in health and disease. The finding that KChIP2 overexpression can prevent the development of the hypertrophic response may have implications for future clinical approaches to heart disease, although extrapolation from rodent to patient should be done with outmost caution. Excessive KChIP2 overexpression increasing *I*~to~ may in spite of an augmented inward *I*~Ca,L~ lead to an early repolarization in mammals associated with a Brugada-like phenotype (Calloe et al., [@B12]). Presently it is unknown whether KChIP2 holds regulatory control in the development of heart failure similar to its central role in the progress of cardiac hypertrophy. Furthermore, the antiarrhythmic properties of KChIP2 are still ill described, notwithstanding its initial report (Kuo et al., [@B41]). Reduced KChIP2 levels confer smaller *I*~Ca,L~ potentially reducing the amplitude of early afterdepolarizations in events of current reactivation at long action potentials, reducing the risk of triggering ventricular arrhythmias. However, optimal KChIP2 levels contribute to maintaining minimal regional repolarization dispersion, thus reducing the substrate for arrhythmias. Nonetheless, KChIP2 is a multipronged modifier of a series of voltage-gated cardiac ion channels and has important physiological functions in health and in heart disease.
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